Published in Gene Therapy Weekly, March 29th, 1999
D.K. Monteith and colleagues from ISIS Pharmaceuticals, California, evaluated progress in the development of synthetic ODNs ("Synthetic Oligonucleotides: The Development of Antisense Therapeutics," Toxicologic Pathology, January-February 1999;27(1):8-13).
"Antisense therapeutics using synthetic oligodeoxynucleotides (ODNs) are currently being evaluated in clinical trials for cancer, inflammation, and viral diseases," wrote Monteith et al. "These macromolecules afford a unique opportunity to treat disease at the molecular level."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.